Skin Permeation of Rosiglitazone from Transdermal Matrix Patches - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Skin Permeation of Rosiglitazone from Transdermal Matrix Patches
The authors demonstrate that sustained-release delivery can help avoid the risk of sudden higher-blood concentration of a drug to avoid toxicity.


Pharmaceutical Technology
Volume 34, Issue 5, pp. 56-72


Figure 7
Furthermore, the patches were evaluated on STZ-induced diabetic and normal-control rats. The patches were applied to the animals' backs (see Figure 1). The average blood-glucose levels of Group III and IV animals were similar to those in diabetic-control Group II animals. The plain patch without drug did not alter the glucose levels of animals in Group III and Group IV. Orally administered rosiglitazone maleate reduced Group VII diabetic animals' blood-glucose level to 140 mg/dl from 250 mg/dl in 12 h. However, the blood-glucose level rose to 220 mg/dl in 24 h. This rise necessitated the additional dose to be given to maintain the glucose level (see Figure 7). Again, it is worth mentioning that the glucose level was not reduced to the level of the control animals (i.e., Group I) upon administering the drug orally or transdermally. This suggests that additional therapy such as insulin analogues may be required because STZ damages islets cells irreversibly. Blood-glucose levels in Group V and Group VI animals were effectively reduced for 48 h to 150 mg/dl, which suggests that the patches controlled blood-glucose levels at least for 48 h in the diabetic rats. Formulation I reduced blood-glucose levels more effectively (i.e., in Group V animals) compared with Formulation II (i.e., in Group VI animals). Although numerical values did not differ greatly, the differences were persistent and statistically significant.

The location of the patch on humans is an important factor because the thickness of skin differs at different locations on the body. Different permeation rates were found at different locations when patch-type formulations of scopolamine hydrobromide were applied behind the ear and on the thigh (24). The steady-state permeation rate of this drug was 10 μg/cm2/h from the patch applied behind the ear, where average skin thickness is 0.084mm. The permeation rate was 4.7 μg/cm2/h from the patch applied on the thigh, where average skin thickness is 0.106 mm. Hence, the authors chose to apply the rosiglitazone transdermal patch to the neck region behind the ear.


Figure 8
The plasma-drug level was determined using HPLC. Figure 8(a) shows the chromatogram of pure drug and internal standard in solvent. Figure 8(b) represents the chromatogram of blank plasma. Figure 8(c) represents the chromatogram of rosiglitazone and pioglitazone in plasma for a standard sample. Figure 8(d) is a representative chromatogram of rosiglitazone in plasma after 8 h in humans, where pioglitazone was used as an internal standard.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here